Developer docs
API playgroundTry for free, no card

Search company profiles

Imophoron

Full company profile

uuid0003544

Namestring
Imophoron
Legal namestring
Imophoron
Websiteurl
imophoron.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Imophoron is a Bristol, UK-based pre-clinical biotechnology company developing ADDomer(TM), a proprietary next-generation vaccine platform currently applied to RSV, Chikungunya, and COVID-19 indications for future healthcare and public-health customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
vaccine development, vaccine platform technology, infectious disease vaccines, rapid response vaccines, viral pathogen vaccines
Industry4 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Vaccine Development
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Imophoron develops a proprietary vaccine platform (ADDomer™) for rapid-response vaccine development against viral pathogens. The company is advancing pre-clinical vaccines targeting respiratory syncytial virus (RSV), Chikungunya virus, and SARS-CoV-2 (COVID-19), focusing on underserved and emerging infectious diseases.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1RSV Vaccine
CategoryVaccine
2Chikungunya Vaccine
CategoryVaccine
3COVID-19 Vaccine
CategoryVaccine
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
1Valneva
TypeDirect peer
Description

European-headquartered specialty vaccine company developing and commercializing travel/tropical-disease vaccines including the first approved Chikungunya vaccine (Ixchiq). Comparable to Imophoron because both target Chikungunya with next-generation vaccine platforms and focus on underserved infectious-disease indications rather than mass-market primary-care vaccines.

TypeBroad incumbent
Description

Public recombinant-protein nanoparticle vaccine company with approved COVID-19 vaccine (Nuvaxovid) and clinical-stage RSV program. Comparable to Imophoron because it operates a protein-subunit/nanoparticle vaccine platform and competes head-to-head in the COVID-19 and RSV target indications.

3Emergex Vaccines
TypeDirect peer
Description

UK-based pre-clinical vaccine developer with a synthetic nanopeptide platform (T-cell primed set-point vaccines) targeting infectious diseases including viral pathogens. Comparable to Imophoron as both are UK early-stage platform companies advancing non-mRNA novel vaccine modalities through pre-clinical stages toward infectious-disease targets.

TypeDirect peer
Description

Oxford-originated vaccine platform company using a proprietary protein 'plug' display technology to create virus-like particles, spun out from the University of Oxford. Highly comparable to Imophoron as a UK VLP-based infectious-disease platform biotech that has attracted major-pharma partnership interest.

TypeBroad incumbent
Description

Established vaccine company with approved smallpox/mpox and chikungunya vaccine (Vimkunya) products. Comparable to Imophoron as a mid-sized specialty vaccine incumbent with direct Chikungunya overlap and a focus on public-health/emerging infectious-disease markets.

TypeBroad incumbent
Description

Large mRNA vaccine company with approved COVID-19 vaccine, RSV vaccine (mResvia), and broad infectious-disease pipeline. Comparable to Imophoron because it competes in the same RSV and COVID-19 indication spaces and defines the alternative 'rapid-response' pandemic-preparedness vaccine-platform business model that Imophoron's ADDomer platform is attempting to emulate.

TypeDirect peer
Description

Clinical-stage European biotech developing non-mRNA viral-vector and VLP-based infectious-disease vaccines using an insect-cell protein production platform. Comparable to Imophoron because both are small, platform-driven vaccine developers targeting infectious-disease indications using non-mRNA novel modalities.

TypeDirect peer
Description

Small-cap vaccine platform company developing enveloped VLP (eVLP) technology targeting infectious diseases including RSV and coronaviruses. Comparable to Imophoron as a similarly-sized, platform-based vaccine developer focused on VLP modalities and overlapping disease targets.

TypeEmerging player
Description

Danish VLP vaccine platform company (cVLP technology) spun out from the University of Copenhagen, with programs in RSV and other infectious diseases. Comparable to Imophoron as a small-cap VLP platform developer pursuing overlapping disease targets including RSV.

TypeBroad incumbent
Description

European mRNA vaccine platform company with broad infectious-disease pipeline and a focus on rapid-response pandemic vaccines. Comparable to Imophoron because it pursues a similar 'platform for rapid vaccine deployment' commercial thesis against infectious diseases.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imophoron

Vaccine Developmentimophoron.com

Imophoron is a Bristol, UK-based pre-clinical biotechnology company developing ADDomer(TM), a proprietary next-generation vaccine platform currently applied to RSV, Chikungunya, and COVID-19 indications for future healthcare and public-health customers.

Imophoron firmographics

Firmographics
Name
Imophoron
Legal name
Imophoron
Website
https://imophoron.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Imophoron is a Bristol, UK-based pre-clinical biotechnology company developing ADDomer(TM), a proprietary next-generation vaccine platform currently applied to RSV, Chikungunya, and COVID-19 indications for future healthcare and public-health customers.
Ownership category
akta.pro rank

Imophoron industry classification

Industry
Product category
Vaccine Development
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines

Keywords

  • Vaccine development
  • Vaccine platform technology
  • Infectious disease vaccines
  • Rapid response vaccines
  • Viral pathogen vaccines

Where Imophoron is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Markets served

Imophoron business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Imophoron product offering

Product offering

Core offering

Imophoron develops a proprietary vaccine platform (ADDomer™) for rapid-response vaccine development against viral pathogens. The company is advancing pre-clinical vaccines targeting respiratory syncytial virus (RSV), Chikungunya virus, and SARS-CoV-2 (COVID-19), focusing on underserved and emerging infectious diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • RSV Vaccine
  • Chikungunya Vaccine
  • COVID-19 Vaccine

Companies that use Imophoron

Customer profile

Segments1 record

Ideal customer profiles1 record

Imophoron technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Imophoron partnerships and signals

Strategic signal

Scale indicators1 record

Imophoron competitors and assessment

Company assessment

Direct peers

  • Valneva: European-headquartered specialty vaccine company developing and commercializing travel/tropical-disease vaccines including the first approved Chikungunya vaccine (Ixchiq). Comparable to Imophoron because both target Chikungunya with next-generation vaccine platforms and focus on underserved infectious-disease indications rather than mass-market primary-care vaccines.
  • Emergex Vaccines: UK-based pre-clinical vaccine developer with a synthetic nanopeptide platform (T-cell primed set-point vaccines) targeting infectious diseases including viral pathogens. Comparable to Imophoron as both are UK early-stage platform companies advancing non-mRNA novel vaccine modalities through pre-clinical stages toward infectious-disease targets.
  • SpyBiotech: Oxford-originated vaccine platform company using a proprietary protein 'plug' display technology to create virus-like particles, spun out from the University of Oxford. Highly comparable to Imophoron as a UK VLP-based infectious-disease platform biotech that has attracted major-pharma partnership interest.
  • ExpreS2ion Biotechnologies: Clinical-stage European biotech developing non-mRNA viral-vector and VLP-based infectious-disease vaccines using an insect-cell protein production platform. Comparable to Imophoron because both are small, platform-driven vaccine developers targeting infectious-disease indications using non-mRNA novel modalities.
  • VBI Vaccines: Small-cap vaccine platform company developing enveloped VLP (eVLP) technology targeting infectious diseases including RSV and coronaviruses. Comparable to Imophoron as a similarly-sized, platform-based vaccine developer focused on VLP modalities and overlapping disease targets.

Broad incumbents

  • Novavax: Public recombinant-protein nanoparticle vaccine company with approved COVID-19 vaccine (Nuvaxovid) and clinical-stage RSV program. Comparable to Imophoron because it operates a protein-subunit/nanoparticle vaccine platform and competes head-to-head in the COVID-19 and RSV target indications.
  • Bavarian Nordic: Established vaccine company with approved smallpox/mpox and chikungunya vaccine (Vimkunya) products. Comparable to Imophoron as a mid-sized specialty vaccine incumbent with direct Chikungunya overlap and a focus on public-health/emerging infectious-disease markets.
  • Moderna: Large mRNA vaccine company with approved COVID-19 vaccine, RSV vaccine (mResvia), and broad infectious-disease pipeline. Comparable to Imophoron because it competes in the same RSV and COVID-19 indication spaces and defines the alternative 'rapid-response' pandemic-preparedness vaccine-platform business model that Imophoron's ADDomer platform is attempting to emulate.
  • CureVac: European mRNA vaccine platform company with broad infectious-disease pipeline and a focus on rapid-response pandemic vaccines. Comparable to Imophoron because it pursues a similar 'platform for rapid vaccine deployment' commercial thesis against infectious diseases.

Emerging players

  • AdaptVac: Danish VLP vaccine platform company (cVLP technology) spun out from the University of Copenhagen, with programs in RSV and other infectious diseases. Comparable to Imophoron as a small-cap VLP platform developer pursuing overlapping disease targets including RSV.

Market position

Customer concentration

Imophoron social profiles

Digital presence

Imophoron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imophoron leadership team

Management profile

Number of profiles

Profiles2 records

Imophoron funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imophoron M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imophoron

What does Imophoron do?

Imophoron develops a proprietary vaccine platform (ADDomer™) for rapid-response vaccine development against viral pathogens. The company is advancing pre-clinical vaccines targeting respiratory syncytial virus (RSV), Chikungunya virus, and SARS-CoV-2 (COVID-19), focusing on underserved and emerging infectious diseases.

Is Imophoron a public or private company?

Imophoron is a private company. It is classified as venture growth investor backed and is currently operating.

When was Imophoron founded?

Imophoron was founded in 2017. It employs 1 to 10 people.

Where is Imophoron based?

Imophoron is headquartered in Bristol, United Kingdom, in the Europe region.

Who are Imophoron's main competitors?

Direct peers on record are Valneva, Emergex Vaccines, SpyBiotech, ExpreS2ion Biotechnologies and VBI Vaccines. Broad incumbents are Novavax, Bavarian Nordic, Moderna and CureVac. AdaptVac is listed as an emerging player.

Does Imophoron have an API?

No public API is recorded for Imophoron.

What industry is Imophoron in?

Imophoron's product category is Vaccine Development. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals